Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| SUMMER INFAN | SUMR | 6.93% |
| FEDERAL MOGU | FDML | 6.24% |
| NATUS MEDICA | BABY | 5.55% |
| NEW ORIENTAL | EDU | 5.40% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Leading firearm manufacturer, Smith & Wesson Holding Corporation ( SWHC - Snapshot Report ) reported adjusted earnings of 24 cents per share in the second quarter of fiscal 2013, compared with 1 cent per share in the year-ago quarter.
The results of the company were a penny higher than the Zacks Consensus Estimate.
Total Revenue
The company reported net sales of $136.6 million in the relevant quarter, up 47.9% from $92.3 million in the year-earlier period. The year-over-year growth was driven by strong sales across all of the company’s product lines, including its M&P product platform.
Net sales in the reported quarter were nominally higher than the Zacks Consensus forecast of $136 million.
Quarterly Highlights
Gross profit grew to 35.5% of net sales from 26.7% in the second quarter of the previous fiscal. Cost reduction initiatives yielded positive results. Operating expenses, as a percentage of revenue, thus declined by 690 basis points year over year.
The company continues to invest consistently in research and development (R&D) activities to develop new products. In the second quarter of fiscal 2013, the company spent $1.27 million on R&D versus $1.24 million in the prior-year quarter.
Operating income clocked $26.6 million versus $3.4 million in the year-earlier period, increasing an astronomical 682.2%.
Smith & Wesson sat on a firearm backlog of $332.7 million, increasing $182.8 million year over year from $149.9 million at the end of the second quarter of last year.
Financial Update
Cash and cash equivalents of Smith & Wesson as of October 31, 2012, were $61.3 million versus $56.7 million as of April 30, 2012.
Cash from/(used in) operating activities was $13.7 million in the second quarter of fiscal 2013 versus ($2.5) million in the second quarter of fiscal 2012.
Guidance
The company expects total revenue in the third quarter of fiscal 2013 in the range of $126 million to $131 million, reflecting 30% year-over-year growth. GAAP earnings per share in the third quarter of fiscal 2013 are expected between 19 cents and 21 cents.
Total revenue for fiscal 2013 is now expected in the range of $550 million to $560 million, up from the prior forecast of $530 million to $540 million. This reflects an estimated 35% year-over-year growth. GAAP earnings per share for fiscal 2013 are expected between $1.00 and $1.05.
At the Peer
The company competes with Sturm, Ruger & Company Inc. ( RGR - Snapshot Report ) . The top- and bottom-line results of Sturm, Ruger & Company in the third quarter were higher than the Zacks Consensus Estimates. The Zacks Consensus earnings estimate for the fourth quarter is currently at 64 cents per share.
Our Take
Smith & Wesson continues to post strong results. The firearm maker has surpassed our expectation for the last six quarters. The company’s decision to buy back shares to increase shareholder value is appreciated.
Though the firearm backlog increased 122.2% year over year to $332.7 million it decreased 15.2% sequentially. Whether the sequential decline is only a seasonal effect or an indicator of a diminishing order book is to be seen in the performance of the future quarters. Smith & Wesson currently retains a short-term Zacks #3 Rank (Hold rating).
Based in Springfield, Massachusetts, Smith & Wesson Holding Corporation was founded in 1852. The company manufactures, designs and supplies a large variety of firearms and related items to its worldwide customers. The company has 1,346 full time employees and a market cap of $0.71 billion.
Read the full reports :
Snapshot Report on RGR
Snapshot Report on SWHC